DIVI S LABORATORIES LTD vs Vivanza Biosciences Ltd

A side-by-side comparison of DIVI S LABORATORIES LTD (DIVISLAB) and Vivanza Biosciences Ltd (VIVANZABIOSCIENCESLTD) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, DIVI S LABORATORIES LTD leads DIVISLAB vs VIVANZABIOSCIENCESLTD on 10 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability40
  • Growth01
  • Size & financial health40
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

94.61
P/E ratio
16.20
10.62
P/B ratio
1.63
0.33%
Dividend yield
0.00%
₹96.73
EPS
₹0.10

Profitability

DIVISLAB takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

16.50%
Return on equity
9.38%
22.00%
Return on capital
6.00%
33.00%
EBITDA margin
1.00%
24.32%
Net margin
0.00%

Growth

VIVANZABIOSCIENCESLTD takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

10.78%
Revenue CAGR (3Y)
86.09%
12.10%
Profit CAGR (3Y) even

Size & financial health

DIVISLAB takes 4/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹2.43L Cr
Market cap
₹7 Cr
₹10,560 Cr
Revenue
₹116 Cr
₹2,568 Cr
Net profit
₹0 Cr
0.00
Debt / equity
2.00
DIVI S LABORATORIES LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
  • ["Stock is trading at 14.6 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
Vivanza Biosciences Ltd
  • + ["Debtor days have improved from 196 to 39.0 days."]
  • ["Promoter holding is low: 20.0%", "Company has a low return on equity of 2.11% over last 3 years.", "Company might be capitalizing the interest cost", "Promoter holding has decreased over last 3 years: -27.8%"]
DIVI S LABORATORIES LTD full analysis Vivanza Biosciences Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.